āshibio Doses First Patient in ANDECAL Study, a Phase II/III Trial of Andecaliximab for Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

0
20
āshibio announced the dosing of the first participant in its ANDECAL study, a Phase II/III clinical trial evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of andecaliximab in patients with FOP.
[āshibio]
Press Release